GET DAILY SIGNALSAkebia Therapeutics (AKBA) and the Path to Its $3.90 Average Analyst Target
Key Takeaways
- The central $3.90 target represents the arithmetic mean of five verified analyst price targets rather than any single firm’s forecast.
- From a recent close near $0.76, reaching $3.90 would require a gain of roughly 410%, a substantial move.
- The target range spans from $1.00 (Leerink Partners, Hold) to $6.00 (H.C. Wainwright, Buy), highlighting significant disagreement on execution risk.
- Key supports include Vafseo commercialization, the kidney-disease pipeline, and a European licensing deal.
- Major risks center on the sub-$1 share price, revenue-recognition issues, and Nasdaq listing compliance concerns.
Analyst Price Targets and the Consensus Picture
Akebia Therapeutics, Inc. (AKBA) focuses on developing and commercializing kidney-disease treatments, with Vafseo (vadadustat) for dialysis-related anemia and Auryxia (ferric citrate) as its main products. I reviewed five current analyst targets: Piper Sandler’s Buy rating at $4.00 (October 2026), BTIG’s Buy at $4.00 (September 2026), WestPark Capital’s Buy at $4.50 (September 2026), Leerink Partners’ Hold at $1.00 (August 2026), and H.C. Wainwright’s Buy at $6.00 (August 2026). The arithmetic mean comes to $3.90 within that wide $1.00-to-$6.00 band.
The spread itself reveals the underlying debate. Differing views on whether Vafseo revenue can scale consistently drive the gap between the cautious $1.00 and optimistic $6.00 targets. While the overall ratings tilt bullish, the broad range suggests treating the average as a directional indicator rather than a precise prediction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and the Scale of the Move
Shares closed near $0.76 in late October 2026, down about 80% over the past year and close to the 52-week low of roughly $0.54. A climb to $3.90 would demand an increase of approximately 410%, underscoring the magnitude involved. Market capitalization sits around $212 million, reflecting the compression the stock has experienced.
Any credible path to the target would likely hinge on sustained Vafseo revenue growth, progress in the praliciguat Phase 2 program for focal segmental glomerulosclerosis, and restored investor confidence after the US Renal Care dosing-protocol change disrupted recognized revenue. Recovery would probably occur through successive re-ratings rather than one decisive event.
Factors That Could Support Progress Toward the Target
The bull case centers on execution. Vafseo targets a sizable dialysis-anemia market, and the most recent quarter showed revenue near $49 million alongside a narrowed net loss of about $9 million. A licensing agreement with Medice extends the commercial reach into Europe, while the praliciguat program adds pipeline flexibility. Insider buying and a mostly Buy-rated analyst group suggest some professionals see meaningful upside from current levels.
Obstacles That Could Keep the Target Out of Reach
Challenges remain significant. Trading below $1 raises structural concerns, and data from Fidelity indicates the company has not met Nasdaq continued-listing requirements. The dosing-protocol adjustment at US Renal Care has created uncertainty around near-term Vafseo sales. Prior target reductions and the latest GAAP net loss reinforce that consistent revenue growth and a clearer route to profitability must come first before a move of this size becomes realistic.
Technical Levels Worth Watching
The stock remains in a clear downtrend after hitting the 52-week low near $0.54 and rebounding to about $0.76. The $1.00 level stands out as both a psychological threshold and a key marker tied to listing status and Leerink’s target. Nearer-term resistance appears in the $0.80–$0.90 zone, while any advance toward $3.90 would need to clear much higher levels without recent price history for reference.
Time Horizon and Items to Monitor
Analyst targets generally reflect a roughly 12-month horizon. Investors should track quarterly Vafseo revenue trends and any additional commentary on the dosing-protocol impact, updates from the praliciguat Phase 2 trial, cash position and financing moves, and progress on Nasdaq compliance. Revisions to price targets, especially further cuts or upgrades, will indicate whether the $1.00-to-$6.00 range is tightening.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical patterns. I find these signals helpful for spotting shifts that complement fundamental analysis like the factors discussed here. For those following AKBA, layering the signals onto the revenue and pipeline details can provide additional day-to-day context.
Final Assessment
Can AKBA reach $3.90? The target is genuine yet demanding: it averages five analyst forecasts but sits roughly 410% above the recent price, and the $1.00-to-$6.00 spread shows deep differences in outlook. The supporting elements—Vafseo commercialization, pipeline assets, and the European partnership—are real, yet they face offsets from the sub-$1 price, revenue disruption, and listing concerns. Achieving the target would require a sustained re-rating that has not yet materialized. Investors should view the figure as a long-term, high-risk scenario and focus on revenue consistency, pipeline developments, financing, and analyst updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AKBA's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for AKBA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where AKBA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AKBA as a result. In 62 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on October 28, 2026. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Following a +18.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 224 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.221) is normal, around the industry mean (8.801). P/E Ratio (-6.185) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs for the treatment of anemia and vascular diseases
Industry PharmaceuticalsGeneric
Advertisement